Optimizing HEK293 media for improved titers and VG/Capsid ratios

Human embryonic kidney (HEK293) cells are the most commonly used cell line to produce viral vectors for gene therapy.

The manufacturing of viral vectors for gene therapy can be a challenging process. Due to the complexity of their production and purification, viral vectors can be very expensive to produce.

To help cell and gene therapy product manufacturers discover the optimal HEK293 media for their viral vector-based applications, FUJIFILM Irvine Scientific has developed the HEK293 Media Survey Panel (HSMP).

The HMSP is a curated panel of six growth media and three feed supplements of high-quality, scalable, CD HEK media. Designed to improve growth and production of AAV and AAV2 serotypes, the HSMP optimizes HEK293 media allowing for increased titers and improved VG/Capsid ratios. Choosing the proper media in a scale-down model for each cell line and process can improve yield and lower production costs as well as managing to the demand for high demand and dosage of the therapeutics.

Learn more about the HEK293 Media Survey panel and discover your optimal media, and streamline the workflow process for viral vector production while increasing transfection efficacy and cell growth consistency. 

• Optimize your HEK293 media for cell and gene therapy, and viral vector-based vaccine applications
• Discover how HMSP growth media can significantly improve growth and production of AAV and AAV2 serotypes
• The advantage of choosing the proper scale-down model for each cell line to improve yield and lower production costs
• Evaluate/Determine/Explore the optimal media for increased titers and VG/capsid ratios for therapeutic development.
• Streamline the workflow process for viral vector production while increasing transfection efficacy and cell growth consistency.

Hamid Soleymani

Scientist at

Hamid Soleymani, Scientist II- Cell and Gene Therapy Group, at Fujifilm Irvine Scientific is a part of the Life Science R&D team and supports the company’s efforts to develop new or improved products, process improvements, and technical support for Cell and Gene Therapies.

Mr. Soleymani’s main role is developing the cell culture formula for improving AAV production in HEK293 cells. With technical expertise in microbial and mammalian molecular biology, cell design, microbial and bioinformatics, Bioprocessing, enzymology, biofuels, and RNA research, Hamid provides a strong research background and technical expertise.

Hamid has a Master of Science in Industrial Biotechnology from Wageningen University in the Netherlands, a Bachelor of Applied Science in Medical Molecular Life Science, from HAN University of Applied Science, also in the Netherlands.

Watch now

SPEAKERS

Hamid Soleymani

Scientist at

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 70

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 41

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 35

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 34

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 33

Days

Register